Next Article in Journal
Yeast–Yeast Interactions: Mechanisms, Methodologies and Impact on Composition
Previous Article in Journal
Effect of Cobalt, Nickel, and Selenium/Tungsten Deficiency on Mesophilic Anaerobic Digestion of Chemically Defined Soluble Organic Compounds
Open AccessArticle

FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells

1
Department of Virology, Veterinary Research Institute, Hudcova 70, CZ-62100 Brno, Czech Republic
2
Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno, Czech Republic
3
Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic
4
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, PMB 5025 Awka 420281, Nigeria
5
Faculty of Science, Masaryk University, Kamenice 5, CZ-625 00 Brno, Czech Republic
*
Author to whom correspondence should be addressed.
Microorganisms 2020, 8(4), 599; https://doi.org/10.3390/microorganisms8040599
Received: 10 February 2020 / Revised: 16 March 2020 / Accepted: 15 April 2020 / Published: 20 April 2020
(This article belongs to the Special Issue Flaviviruses—Antivirals and Vaccines)
Vector-borne flaviviruses (VBFs) affect human health worldwide, but no approved drugs are available specifically to treat VBF-associated infections. Here, we performed in silico screening of a library of U.S. Food and Drug Administration-approved antiviral drugs for their interaction with Zika virus proteins. Twelve hit drugs were identified by the docking experiments and tested in cell-based antiviral assay systems. Efavirenz, tipranavir, and dasabuvir at micromolar concentrations were identified to inhibit all VBFs tested; i.e., two representatives of mosquito-borne flaviviruses (Zika and West Nile viruses) and one representative of flaviviruses transmitted by ticks (tick-borne encephalitis virus). The results warrant further research into these drugs, either individually or in combination, as possible pan-flavivirus inhibitors. View Full-Text
Keywords: FDA; flavivirus; Zika virus; tick-borne encephalitis virus; West Nile virus; antiviral FDA; flavivirus; Zika virus; tick-borne encephalitis virus; West Nile virus; antiviral
Show Figures

Figure 1

MDPI and ACS Style

Stefanik, M.; Valdes, J.J.; Ezebuo, F.C.; Haviernik, J.; Uzochukwu, I.C.; Fojtikova, M.; Salat, J.; Eyer, L.; Ruzek, D. FDA-Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses in Vero Cells. Microorganisms 2020, 8, 599.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop